Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$30.79
+1.7%
$26.59
$23.15
$129.39
$11.89B1.848.66 million shs5.32 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.51
+0.7%
$23.62
$20.92
$31.54
$145.01B0.5841.49 million shs18.53 million shs
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$135.73
+0.3%
$134.25
$127.35
$159.64
$34.52B0.78.79 million shs5.28 million shs
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
+5.54%+12.73%+11.94%+17.68%-74.14%
Pfizer Inc. stock logo
PFE
Pfizer
+1.16%+4.24%+8.00%+4.22%-9.02%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
-0.99%+1.09%+1.99%-5.43%-6.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.3732 of 5 stars
4.02.00.04.61.22.50.6
Pfizer Inc. stock logo
PFE
Pfizer
4.8839 of 5 stars
2.33.04.24.32.81.73.1
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6151.40% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1714.36% Upside
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
2.69
Moderate Buy$135.49-0.18% Downside

Current Analyst Ratings Breakdown

Latest PFE, XLV, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$32.00 ➝ $28.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$50.00 ➝ $32.00
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/17/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
4/9/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$39.00 ➝ $32.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.14B3.79N/AN/A$28.33 per share1.09
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.28$4.44 per share5.74$15.62 per share1.63
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3818.488.420.9112.62%20.33%8.53%8/5/2025 (Estimated)
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/A21.15N/AN/AN/AN/AN/A

Latest PFE, XLV, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.74%N/A124.64%16 Years
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
$2.391.76%N/AN/AN/A

Latest PFE, XLV, and MRNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable
Health Care Select Sector SPDR Fund stock logo
XLV
Health Care Select Sector SPDR Fund
N/A254.47 millionN/ANot Optionable

Recent News About These Companies

6 ETFs to Invest in June
Healthcare ETFs Slide as UnitedHealth Plunges
Young woman doctor holding a tablet pc — Photo
Top Analyst-Rated Healthcare Stocks to Watch Now (XLV)
...
SPDR Health Care Select Sector (XLV)
Health Care Sector In 2025: Buy Abbott Labs

New MarketBeat Followers Over Time

Media Sentiment Over Time

Moderna stock logo

Moderna NASDAQ:MRNA

$30.79 +0.51 (+1.67%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer stock logo

Pfizer NYSE:PFE

$25.50 +0.19 (+0.73%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Health Care Select Sector SPDR Fund stock logo

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$135.73 +0.37 (+0.27%)
As of 12:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.